Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 14, 2011

Roslin Cellab Adopts Alcohol-Free BioCision's Cryopreservation Tool

  • Roslin Cellab will replace its conventional tools for cryopreservation of human embryonic stem cell lines with BioCision®'s alcohol-free CoolCell® freezing container. Roslin Cellab had been using a cell-freezing container that required the use of 100% isopropyl alcohol for stepwise (-1 degree C/minute) cooling of cell lines in a -80 degree C freezer. That alcohol required frequent changing, a process the company says was costly and cumbersome.

    CoolCell delivers a cooling rate of -1 degree C/minute and identical freezing profiles each time, according to BioCision. “Our cell lines were recovered with reproducibly higher viability yields post-thaw, and subsequent ongoing growth was improved," says John Gardner, senior project leader at Roslin Cellab. "This suggests that the freezing rate is more accurate than the isopropyl alcohol method, which is crucial if a cell line is to survive cryopreservation."

    BioCision CEO Rolf Ehrhardt, M.D., Ph.D., says that CoolCell enhances cryopreservation for stem cells, PBMCs, cell lines, and other cell types, “as well as in other areas of research in which the accuracy of freezing rates is critical.”

    In addition to its CoolCell products, Roslin Cellab is deploying BioCision's ThermalTray™ and CoolRack® modules, which eliminate direct sample contact with ice, water, or liquid nitrogen. The modules can be placed in a 37 degree C water bath, a temperature designed to aid the sterile thawing of cryovials for tissue culture procedures, as well as deliver consistent and reproducible thawing profiles.

    Roslin Cellab assists scientists and technologists with proof-of-concept research, with the goal of translating stem cell research into commercially viable technologies. The company is a subsidiary of the Roslin Foundation and sister company to Roslin Cells, which specializes in the isolation of new clinical-grade undifferentiated stem cells for use in research and therapy.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »